Cancer Biomarkers Market to Reach USD 32.5 Billion by 2031 | 12.3% CAGR Growth | Driven by AI, Omics, and Liquid Biopsy

Cancer Biomarkers Market to grow from USD 13.2 Billion in 2022 to USD 32.5 Billion by 2031 at 12.3% CAGR, led by AI and liquid biopsy.

AUSTIN, TX, UNITED STATES, August 25, 2025 /EINPresswire.com/ -- The Cancer Biomarkers Market was valued at approximately USD 13.2 billion in 2022 and is projected to reach USD 32.5 billion by 2031, registering a strong compound annual growth rate (CAGR) of 12.3% during the forecast period 2024–2031, according to DataM Intelligence. These figures highlight the rapid pace of expansion driven by increasing cancer incidence worldwide, technological breakthroughs, and growing adoption of personalized medicine solutions.
The global Cancer Biomarkers Market is experiencing robust expansion as clinicians, researchers, and diagnostics companies increasingly rely on molecular indicators to detect, diagnose, monitor, and personalize cancer care.

Cancer biomarkers-biological molecules signaling the presence or progression of cancer - span proteins, genes, and other entities detectable in blood, tissue, or body fluids. Their applications extend from disease screening and diagnosis to prognostic assessment, treatment guidance, and drug development. This surge in utility is fueling clinical and commercial adoption, anchored by advancing technologies such as genomics, proteomics, liquid biopsy, bioinformatics, and AI-based analytics.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/cancer-biomarkers-market

Key growth drivers include the escalating global cancer burden, heightened emphasis on early detection, integration of artificial intelligence, adoption of personalized and targeted therapies, and strategic investments by leading diagnostic firms. Within segmentation, profiling technologies such as omics technologies, immunoassays, and bioinformatics are gaining prominence, while geographically, North America currently dominates the market-driven by mature healthcare systems, widespread adoption of advanced diagnostics, and strong R&D infrastructure. Meanwhile, Asia-Pacific emerges as the fastest-growing region, propelled by rising cancer incidence, improving healthcare access, and increasing funding.

Key Highlights from the Report

➤ Global Cancer Biomarkers Market estimated at USD 13.2 billion (2022) and forecast to reach USD 32.5 billion by 2031.
➤ Projected CAGR of 12.3% between 2024 and 2031.
➤ North America is the largest regional market; Asia-Pacific is the fastest-growing region.
➤ Leading technologies include omics, cytogenetics, immunoassays, imaging, and bioinformatics.
➤ Cancer indications segmentation spans breast, lung, colorectal, cervical, sarcoma-breast cancer being notably dominant.
➤ Market fueled by rising cancer prevalence, personalized medicine trends, technological advances, and strategic collaborations.

Market Segmentation

The Cancer Biomarkers Market can be segmented on the basis of cancer indication, biomarker type, profiling technology, application, and end-user, each playing a vital role in shaping overall market dynamics.

By Cancer Indication, the market encompasses breast, lung, colorectal, cervical, prostate, and other cancers. Among these, breast cancer accounts for a dominant share, supported by its high global prevalence and established screening programs that integrate biomarker-based diagnostics. Lung and colorectal cancers are also significant segments due to the increasing adoption of non-invasive biomarker tests, particularly liquid biopsy, for early-stage detection and monitoring.

By Biomarker Type, the market is classified into protein biomarkers, genetic biomarkers, and others such as epigenetic and immunological markers. Protein biomarkers continue to hold a major share owing to their widespread clinical use in cancer detection and monitoring. However, genetic biomarkers are emerging rapidly as advancements in genomics and next-generation sequencing enable highly precise insights into cancer pathways, treatment response, and personalized therapy design.

By Profiling Technology, the market is segmented into omics technologies, cytogenetics, immunoassays, imaging technologies, and bioinformatics tools. Omics technologies—including genomics, proteomics, and transcriptomics—are increasingly applied to discover new biomarkers and improve diagnostic accuracy. Immunoassays remain widely used due to their ability to deliver fast and cost-effective results, while imaging technologies add value in confirming tumor progression and treatment outcomes. Meanwhile, bioinformatics platforms are growing in importance, as they support the interpretation of complex multi-omics datasets and integrate artificial intelligence to accelerate biomarker discovery.

By Application, cancer biomarkers are utilized in disease screening and diagnosis, drug discovery and development, personalized treatment planning, prognosis, and monitoring recurrence. The use of biomarkers in early screening and diagnosis has seen particularly strong growth, driven by the global focus on detecting cancers at earlier stages where treatment outcomes are better. Pharmaceutical companies are also leveraging biomarkers in drug development to accelerate clinical trials, stratify patients, and improve drug efficacy.

By End-User, the market is divided into diagnostic laboratories, hospitals and cancer clinics, academic and research institutes, and pharmaceutical and biotechnology companies. Diagnostic laboratories dominate this segment due to their role in performing specialized tests at scale, while hospitals and cancer clinics rely on biomarker testing for real-time treatment decisions. Academic institutes and research organizations continue to play an essential role in discovering and validating new biomarkers, while pharma and biotech companies increasingly integrate biomarkers into clinical trial design and drug commercialization.

Looking For A Detailed Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=cancer-biomarkers-market

Regional Insights

North America
As the largest regional market, North America benefits from advanced healthcare infrastructure, strong reimbursement systems, active research institutions, and adoption of next-gen diagnostics. The U.S., in particular, leads in biomarker clinical applications and commercialization.

Europe
Europe follows with notable growth, driven by government-backed cancer screening programs, public-private collaborations, and well-regulated adoption of novel diagnostics. The region’s emphasis on precision medicine bolsters demand for biomarker-based tests.

Asia-Pacific
The fastest-growing region, Asia-Pacific, is witnessing rapid expansion attributed to growing cancer incidence, rising healthcare expenditure, increased geriatric populations, greater awareness, and government funding. Key markets include China, India, Japan, and Southeast Asia, where demand for affordable, early-stage diagnostics is surging.

Latin America & Middle East & Africa
These regions span developing healthcare ecosystems. Growth is more gradual but steady, as infrastructure upgrades, expanding screening programs, and multinational lab expansion push adoption. Affordability and access remain notable challenges but are gradually being addressed through collaborations and investments.

Market Dynamics

Market Drivers
The escalating global cancer prevalence remains the principal growth engine. Millions of cancer cases are reported annually worldwide, underscoring the need for early, accurate diagnostics. Additionally, technological strides in liquid biopsies, omics, AI analytics, personalized medicine, and targeted therapies are fueling demand. Strategic partnerships, mergers, and launches by key players are further propelling market momentum.

Market Restraints
Despite strong growth, the market faces constraints. High costs of advanced biomarker tests and equipment can limit adoption in cost-sensitive regions. Regulatory challenges, lengthy validation timelines, reimbursement policies, and infrastructure limitations especially in developing markets can slow deployment. Moreover, complexity in biomarker discovery and clinical validation remains a hurdle.

Market Opportunities
Opportunities abound in expanding early-diagnosis tools like liquid biopsy for minimal residual disease detection, integration of AI-driven analytics, and growing applications in personalized oncology. Emerging markets represent fertile ground for affordable testing solutions. Collaborations between diagnostics companies and healthcare systems, as well as governmental support for cancer programs, open avenues for growth and innovation.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-biomarkers-market

Reasons to Buy the Report

✔ Comprehensive market sizing and forecasts through 2031, offering clarity on growth trajectories.
✔ Detailed segmentation across indication, technology, application, and regional layers.
✔ Insight into leading and emerging players, competitive landscape, and strategic initiatives.
✔ Evaluation of market dynamics drivers, restraints, and opportunities—for informed decision-making.
✔ Data-rich, actionable insights for stakeholders including diagnostics firms, biotech investors, healthcare planners, and policymakers.

Frequently Asked Questions (FAQs)

◆ How big is the Cancer Biomarkers Market?
◆ What is the Projected Growth Rate (CAGR) of the Cancer Biomarkers Market?
◆ Which Region is Estimated to Dominate the Cancer Biomarkers Market through the Forecast Period?
◆ What is the Market Forecast Size by 2031?
◆ Who are the Key Players in the Global Cancer Biomarkers Market?

Company Insights

Key players operating in the Cancer Biomarkers Market include:

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific, Inc.
• QIAGEN N.V.
• Abbott
• Allergan
• Candela Medical Inc
• Bausch Health Companies

Recent Developments:

The rise of liquid biopsy and minimal residual disease (MRD) detection efforts with companies launching blood-based diagnostic innovations highlights a new wave of transformative oncology diagnostics.

Additionally, advances in AI and omics technologies are driving faster biomarker discovery and predictive analytics, expanding applications across early detection and personalized therapy planning.

Conclusion

In summary, the Cancer Biomarkers Market stands at the cusp of transformational growth, buoyed by rising cancer prevalence, technological innovation, and shifting paradigms in healthcare toward precision diagnostics and personalized treatment. From robust market forecasts-USD 13.2 billion in 2022 climbing to potentially USD 32.5 billion by 2031 at a high CAGR-to diverse segmentation across biomarker types, technologies, applications, and geographies, the opportunity landscape is substantial. North America leads the charge today, while Asia-Pacific emerges as a dynamic growth frontier. Continued progress in AI, liquid biopsy, and omics will deepen biomarker adoption, while strategic collaborations and tailored accessibility will unlock new markets. For stakeholders across diagnostics, biotech, healthcare, and policy, investing in biomarker innovations offers both clinical impact and commercial potential for the decade ahead.
Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Competitive Landscape
Sustainability Impact Analysis
KOL / Stakeholder Insights
Unmet Needs & Positioning, Pricing & Market Access Snapshots
Market Volatility & Emerging Risks Analysis
Quarterly Industry Report Updated
Live Market & Pricing Trends
Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Related Reports:

Breast Prosthesis Market

Body Contouring Devices Market

Sai Kiran
DataM Intelligence 4Market Research
+1 877-441-4866
email us here
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.